Literature DB >> 9355970

Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma.

A J Marrogi1, A Munshi, A J Merogi, Y Ohadike, A El-Habashi, O L Marrogi, S M Freeman.   

Abstract

Cytokines and growth factors are powerful modulators of the immune response. Their aberrant expression either by the tumor cells or by the tumor infiltrating lymphocytes confers a selective advantage to the tumor to grow and suppress the cytotoxic activity of the infiltrating lymphocytes. Therefore, analysis of these soluble factors in the tumor microenvironment can provide an insight into the understanding of the tumor behavior and may be used as a prognostic factor. In the present study the nature of the tumor infiltrating lymphocytes (TILs) and cytokine profile was examined in 36 and 19 mammary carcinoma tissues, respectively, by immunohistochemistry and PCR. Phenotypic differences in the number of cytotoxic T lymphocytes (CD8+) and lymphokine activated killer cells (CD16) was observed among TILs when patients with either early disease stage (39% and 46.6%, respectively) or those alive with no residual disease (31% and 52%, respectively) were compared with late stage (9.7% and 22.8%, respectively) or those dead of disease (14.6% and 15.6%, respectively). Furthermore, analysis of the 19 tumor samples for cytokine mRNA expression by RT-PCR revealed the presence of TNF-alpha, IL-10, TGF-beta1, and IL-2. However, semi-quantitative PCR analysis demonstrated TGF-beta1 expression to be significantly higher in patients with a favorable outcome (1.0246 attomoles/micromoles) as compared to patients with a poor prognosis (0.1157 attomoles/micromoles). Our results demonstrate the potential biological significance of certain host factors, particularly TILs and TGFbeta1 expression, on the outcome of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355970     DOI: 10.1002/(sici)1097-0215(19971021)74:5<492::aid-ijc3>3.0.co;2-z

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

Review 1.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

Review 2.  Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.

Authors:  F M Hofman; A Stathopoulos; C A Kruse; T C Chen; V E J C Schijns
Journal:  Anticancer Agents Med Chem       Date:  2010-07       Impact factor: 2.505

3.  Many Roles of CCL20: Emphasis on Breast Cancer.

Authors:  Kingsley O Osuala; Bonnie F Sloane
Journal:  Postdoc J       Date:  2014-03

4.  Anti-angiogenesis immunotherapy.

Authors:  Jonathan D Schoenfeld; Glenn Dranoff
Journal:  Hum Vaccin       Date:  2011-09-01

5.  Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma.

Authors:  Hwa Kyung Byun; Nalee Kim; Sangjoon Park; Jinsil Seong
Journal:  Strahlenther Onkol       Date:  2019-04-15       Impact factor: 3.621

Review 6.  Checkpoint blockade in cancer immunotherapy.

Authors:  Alan J Korman; Karl S Peggs; James P Allison
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

7.  Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J O'Callaghan; J K Collins; F Shanahan
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

Review 8.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

Review 9.  Immunotherapy as a Potential Treatment for Chordoma: a Review.

Authors:  Shalin S Patel; Joseph H Schwab
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

Review 10.  Prospects and challenges of building a cancer vaccine targeting telomerase.

Authors:  Robert H Vonderheide
Journal:  Biochimie       Date:  2007-07-17       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.